Johnson & Johnson Wins FDA Approval for TREMFYA to Prevent Joint Damage

Johnson & Johnson received FDA approval for a supplemental Biologics License Application for its drug TREMFYA (guselkumab).

The expanded label includes efficacy in inhibiting the progression of structural joint damage in adults with active psoriatic arthritis (PsA).

TREMFYA is now the only IL-23 inhibitor with this proven capability to prevent irreversible joint damage.

This regulatory milestone strengthens the company’s immunology franchise and establishes the drug as a potential first-line treatment.

The approval is expected to drive increased clinical adoption and improve the drug’s long-term sales trajectory.

For investors in healthcare ETFs like IYH, the news validates the strength of J&J’s pharmaceutical R&D pipeline.